AdimrSC-2f Uses, Dosage, Side Effects and more
The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia. A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine.
| Trade Name | AdimrSC-2f |
| Generic | AdimrSC-2f |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
